In spite of significant advances in SCS technology, there is still a 20% failure rate in long term SCS therapy primarily due to loss of analgesic benefit. Participants will learn what physiological, pharmacological, and electromechanical factors may contribute to this failure rate and what steps can be implemented to improve long term SCS success.
Determinants of SCS Failures: Opioids, Lack of Sustained Analgesia, and SCS Tolerance/Adaptation
Peter Staats, MBA MD
Advances in SCS Pharmacology
Magdalena Anitescu, MD PhD
Programming Approaches to Solve Failure of SCS Analgesia
Lawrence Poree, MD MPH PhD
- Discuss physiological, pharmacological, and electromechanical factors that may contribute to a failure rate in long term SCS therapy.
- Identify strategies to improve long-term SCS success.
- Neuromodulation Review 2 (305)
- The Promise and Reality of Regenerative Medicine in Pain Management (307)
- Diagnostic and Prognostic Anesthetic Blocks for Facet, Sacroiliac, and Knee Joint Pain: An Evidence-Based Update (202)
- Frontiers in Denervation for Chronic Pain: Sacroiliac Joint Complex, Knee, Shoulder, and Hip (206)
- Lumbar Facet Block and Radiofrequency Ablation International Consensus Guidelines Part 1 (210)